Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Amador Bio Raises $60 Million for Translational/Pharmacology CRO Services

publication date: Dec 31, 2021

Amador BioSciences, a Bay Area CRO, completed a $60 million Series B+ financing from China investors to support its translational sciences and clinical pharmacology services. The company will use the proceeds to increase its offerings to include bioanalytical services. It will also develop AI and machine learning tools to facilitate clinical data analysis. Amador recently acquired Ann Arbor Pharmacometrics Group, which offers high-quality pharmacometrics analysis. The B+ round was led by MSA Capital of Beijing and included Series B co-leads GL Ventures and Sequoia Capital China, along with Co-win Ventures of Beijing. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital